Payden & Rygel Acquires 57,300 Shares of AbbVie Inc. $ABBV

Payden & Rygel increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 52,090.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,410 shares of the company’s stock after buying an additional 57,300 shares during the period. Payden & Rygel’s holdings in AbbVie were worth $13,293,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Brighton Jones LLC raised its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC increased its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. raised its holdings in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after purchasing an additional 789 shares during the last quarter. Curio Wealth LLC lifted its position in shares of AbbVie by 10,466.7% in the 2nd quarter. Curio Wealth LLC now owns 317 shares of the company’s stock worth $59,000 after purchasing an additional 314 shares during the period. Finally, Stegent Equity Advisors Inc. boosted its stake in shares of AbbVie by 79.3% in the 2nd quarter. Stegent Equity Advisors Inc. now owns 8,000 shares of the company’s stock valued at $1,485,000 after purchasing an additional 3,538 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ABBV shares. UBS Group lowered their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Piper Sandler lifted their price objective on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a report on Tuesday, November 4th. Finally, Scotiabank assumed coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.79.

AbbVie Stock Performance

ABBV stock opened at $224.94 on Monday. The stock’s 50 day simple moving average is $224.04 and its 200 day simple moving average is $222.24. The company has a market cap of $397.56 billion, a P/E ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the company posted $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.